<DOC>
	<DOCNO>NCT02106104</DOCNO>
	<brief_summary>The aim study detail ( mechanisms underlie ) action DPP-4 inhibitor linagliptin renal system patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Renal Effects DPP-4 Inhibitor Linagliptin Type 2 Diabetes</brief_title>
	<detailed_description>Based preclinical small-sized study non-diabetic individual , incretin-based therapy , i.e . glucagon-like peptide ( GLP ) -1 receptor agonist dipeptidyl peptidase-4 inhibitor ( DPP-4i ) , may hold promise prevent onset progression diabetic kidney disease . However , potential renoprotective effect agent , believe effectuate `` beyond glucose control '' , sufficiently detail human diabetes . Therefore , present study aim explore mechanistic clinical effect DPP-4i fast postprandial renal physiology biomarkers patient type 2 diabetes . Forty-eight patient type 2 diabetes undergo eight week intervention linagliptin glimepiride order ass change outcome parameter .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Patients type 2 diabetes ( HbA1c : 6.59.0 % DCCT 4875 mmol/mol IFCC ) Metformin monotherapy ; use stable dose least 3 month prior inclusion Both gender ( female must postmenopausal ) Caucasian Age : 3575 year Body Mass Index : &gt; 25 kg/m2 All patient previously diagnose hypertension use RASinterfering agent ( angiotensin convert enzyme inhibitor/angiotensin II receptor blocker ) least 3 month Current / chronic use follow medication : thiazolidinediones , insulin , glucocorticoid , immune suppressant , antimicrobial agent chemotherapeutics . Subjects diuretic exclude drug ( e.g . hydrochlorothiazide ) stop duration study Chronic use NSAIDs allow , unless use incidental medication ( 12 tablet ) nonchronic indication . However , drug take within timeframe 2 week prior renaltesting Pregnancy Frequent occurrence ( confirm ) hypoglycemia ( plasma glucose &lt; 3.9 mmol/L ) Estimated Glomerular Filtration Rate &lt; 60 mL/min/1.73m2 ( determine Modification Diet Renal Disease ( MDRD ) study equation ) Current urinary tract infection active nephritis Recent ( &lt; 6 month ) history cardiovascular disease , include : acute coronary syndrome , chronic heart failure ( New York Heart Association grade IIIV ) , stroke , transient ischemic neurologic disorder Complaints compatible establish gastroparesis and/or neurogenic bladder Active liver disease History actual pancreatic disease History actual malignancy ( except basal cell carcinoma ) History actual severe mental disease Substance abuse ( alcohol : define &gt; 4 units/day ; smoking/nicotine : define daily smoking/use ) Allergy agent use study Inability understand study protocol give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Diabetic kidney disease</keyword>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Renoprotection</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>SU derivative</keyword>
	<keyword>Glimepiride</keyword>
</DOC>